Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders
Rhea-AI Summary
Wellgistics Health (NASDAQ:WGRX) signed a non-exclusive, non-binding $105,000,000 Letter of Intent dated March 23, 2026 to evaluate a potential all-stock acquisition of Neuritek Therapeutics, a neuroscience-focused research organization.
The proposed deal aims to expand Wellgistics' pharmacy distribution and AI-driven patient access platform by adding research and drug-development capabilities; it remains subject to due diligence, definitive agreements, board approvals, and customary closing conditions with no assurance of completion.
Positive
- $105,000,000 LOI to evaluate acquisition of Neuritek
- All-stock structure aligns merger with existing shareholders
- Aims to integrate research with commercialization capabilities
Negative
- LOI is non-binding; no assurance the transaction will close
- Deal subject to due diligence and board approvals
- All-stock transaction could dilute existing shareholders
News Market Reaction – WGRX
On the day this news was published, WGRX declined 8.03%, reflecting a notable negative market reaction. Argus tracked a peak move of +24.7% during that session. Argus tracked a trough of -23.3% from its starting point during tracking. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $13M at that time. Trading volume was elevated at 2.6x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
WGRX rose 14.26% while 4 tracked peers in momentum data moved down (median about -6.6%), indicating a stock-specific reaction rather than a sector-wide move.
Previous Acquisition Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 04 | Acquisition LOI | Positive | -4.5% | Non-binding all-stock LOI to acquire Kare Rx Hub to expand telehealth pharmacy. |
| Apr 10 | Definitive acquisition | Positive | -9.1% | Definitive agreement to acquire Peek Healthcare’s digital prescription marketplace and services. |
Prior acquisition-related announcements were framed as strategic positives but saw negative next-day price reactions, suggesting a history of investor skepticism around M&A news.
Recent history for Wellgistics shows an acquisition-driven expansion strategy. Past deals include a definitive agreement to buy Peek Healthcare Technologies supporting over 2,500 patients and $1.5MM in annual revenue, and an all-stock LOI to acquire Kare Rx Hub with over 500 provider and >200 pharmacy relationships. Both acquisition announcements saw negative 24-hour price moves, so today’s positive reaction reflects a departure from that pattern for similar news.
Historical Comparison
In the past, WGRX’s acquisition headlines produced an average -6.79% next-day move. Today’s +14.26% reaction to another acquisition LOI is a notable outlier versus that pattern.
The company has repeatedly used acquisitions and LOIs to build a broader digital and telehealth pharmacy ecosystem. Today’s neuroscience-focused LOI continues this acquisitive growth strategy into adjacent healthcare and life science capabilities.
Market Pulse Summary
The stock moved -8.0% in the session following this news. A negative reaction despite strategic acquisition news would have fit WGRX’s prior pattern, where past deals saw an average -6.79% move after announcement. In such cases, market focus tended to remain on balance-sheet obligations and execution risk rather than potential synergies. With the stock trading far below its 200-day MA, investors have previously demanded clear evidence that announced transactions progress from LOIs to accretive, integrated operations.
Key Terms
letter of intent financial
all stock transaction financial
AI-generated analysis. Not financial advice.
TAMPA, FL / ACCESS Newswire / March 23, 2026 / Wellgistics Health, Inc. ("Wellgistics" or the "Company") (NASDAQ:WGRX) today announced that it has entered into a non-exclusive, non-binding Letter of Intent ("LOI") to evaluate a potential acquisition of Neuritek Therapeutics, a neuroscience-focused research organization.
The proposed all stock transaction, if completed, is intended to enhance Wellgistics' existing revenue-generating healthcare platform by expanding capabilities adjacent to its core technology-enabled pharmacy distribution and services business. Through its integrated ecosystem spanning prescription fulfillment, wholesale distribution, and AI-driven patient access solutions, Wellgistics connects manufacturers, providers, and a nationwide network of independent pharmacies. The Company believes that adding a research-focused organization could strengthen alignment between drug development and commercialization, enabling earlier engagement with pharmaceutical partners, improving pipeline visibility, and supporting incremental revenue opportunities while enhancing long-term shareholder value through a more integrated and differentiated platform.
The transaction remains subject to the completion of due diligence, negotiation and execution of definitive agreements, approval by the boards of directors of the respective parties, and other customary closing conditions. There can be no assurance that a definitive agreement will be entered into or that the proposed transaction will be consummated on the terms currently contemplated, or at all. The LOI is non-binding and does not obligate either party to complete the proposed transaction. The scope, structure, and terms of any potential transaction remain under evaluation and may change materially as a result of ongoing diligence and negotiations.
The Company is also actively evaluating additional strategic opportunities across the healthcare and life science sectors as part of its broader growth strategy. These opportunities may include acquisitions, partnerships, or other strategic transactions. There can be no assurance that any such initiatives will result in completed transactions.
About Wellgistics Health, Inc
Wellgistics Health is a rapidly scaling, technology-driven healthcare platform positioned at the center of pharmaceutical distribution and patient access. The Company has built an integrated, high-performance ecosystem spanning wholesale distribution, prescription fulfillment, and AI-powered access solutions, directly connecting pharmaceutical manufacturers, healthcare providers, and a nationwide network of independent pharmacies.
By combining infrastructure, data, and intelligent automation, Wellgistics is executing on a capital-efficient model designed to capture significant share in large and fragmented healthcare markets. The Company is focused on expanding high-margin revenue streams, deepening strategic manufacturer relationships, and driving operating leverage across its platform. With a differentiated end-to-end offering and disciplined execution, Wellgistics is positioned to accelerate growth, enhance earnings visibility, and deliver outsized long-term value for shareholders.
About Neuritek Therapeutics Inc.
Neuritek Therapeutics Inc. has developed a next-generation bio-mechanism based treatment, treating the root cause of Post-Traumatic Stress Disorder (PTSD). Neuritek's first to market treatment is an orally active inhibitor of fatty acid amide hydrolase type 1 (FAAH1), the enzyme responsible for metabolizing anandamide (AEA) and the first mechanisms-based treatment for PTSD. The company was founded by Doctor William Hapworth MD., a pioneer in clinical research and a practicing psychiatrist with over 30 years' experience.
Learn more at www.neuritek.com or join the conversation at LinkedIn, neuritek-therapeutics-inc
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable federal securities laws. These forward-looking statements include, without limitation, statements regarding: the potential acquisition of Neuritek Therapeutics, Inc. ("Neuritek"), including the anticipated structure, valuation, timing, and likelihood of completion of any transaction; the preliminary and non-binding nature of the letter of intent; the potential strategic, operational, and financial benefits of any such transaction; the Company's ability to negotiate and enter into definitive agreements; the Company's ability to obtain any required financing; the integration of any acquired business; and the Company's broader growth strategy and future performance.
Forward-looking statements may be identified by words such as "may," "could," "would," "should," "expect," "anticipate," "believe," "intend," "plan," "project," "estimate," "potential," "opportunity," "target," "forecast," "continue," "will," and similar expressions.
These forward-looking statements are based on current expectations, assumptions, and estimates and are subject to significant risks and uncertainties, many of which are beyond the Company's control. Important factors that could cause actual results to differ materially include, but are not limited to: the risk that the parties do not enter into definitive agreements; the risk that the letter of intent is terminated or does not result in a completed transaction; uncertainties related to the preliminary nature of the proposed valuation and transaction terms, which may change materially; the risk that any required financing is not obtained on acceptable terms or at all; the risk that anticipated benefits of any transaction are not realized; risks associated with integrating a research-focused organization into the Company's existing business; risks related to the development, testing, regulatory approval, and commercialization of pharmaceutical or therapeutic products, including the possibility of unfavorable clinical results or delays; regulatory and compliance risks; and other risks and uncertainties described from time to time in the Company's filings with the U.S. Securities and Exchange Commission.
Forward-looking statements speak only as of the date they are made, and undue reliance should not be placed on such statements. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.
Wellgistics Media & Investor Contact
Media: media@wellgisticshealth.com
Investor Relations: IR@wellgisticshealth.com
SOURCE: Wellgistics Health, Inc.
View the original press release on ACCESS Newswire
FAQ
What did Wellgistics (WGRX) announce on March 23, 2026 regarding Neuritek?
How would the proposed Neuritek acquisition affect Wellgistics' business strategy (WGRX)?
Is the $105,000,000 LOI between Wellgistics (WGRX) and Neuritek binding?
Will the proposed all-stock deal for Neuritek cause dilution for WGRX shareholders?
What are the next steps and timeline for the Wellgistics (WGRX) potential acquisition of Neuritek?
Could Wellgistics (WGRX) pursue other strategic deals besides Neuritek?
